Phase 2 Trial of T-cell Based Low-dose Cyclophosphamide and Outpatient Intravenous Interleukin-2 in Metastatic Melanoma

Trial Profile

Phase 2 Trial of T-cell Based Low-dose Cyclophosphamide and Outpatient Intravenous Interleukin-2 in Metastatic Melanoma

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Cyclophosphamide (Primary) ; Interleukin-2
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jun 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record
    • 12 Jan 2014 Planned End Date changed from 1 Oct 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov record
    • 27 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top